RecruitingNot Applicable

Triple Assay of Rectal Mucus in the Diagnosis of Colorectal Cancer

United Kingdom6,600 participantsStarted 2024-11-01

Plain-language summary

Development of a multiomics assay for use on OriColTM sampled rectal mucus for detection of cancer and significant polyps in symptomatic patients on the Colorectal Urgent Suspected Cancer pathway.

Who can participate

Age range18 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Patients 18 years and over
✓. Patients referred from primary care to the 'urgent suspected cancer' CRC pathway during the study period.
✓. Patients who provide voluntary written informed consent to participate in the study.

Exclusion criteria

✕. Patients who are unable to undergo digital rectal examination (DRE).
✕. Patients with peri-anal/anal symptoms that may limit DRE and proctoscopy examination and it would be clinically inappropriate to attempt to assess these patients. This may include conditions such as:
✕. Current pregnancy or suspicion of pregnancy.

What they're measuring

TRIOMIC - 1

Timeframe: 26 months

TRIOMIC - 2

Timeframe: 26 month

TRIOMIC - 3

Timeframe: 26 months

Trial details

NCT IDNCT06649123

SponsorOrigin Sciences

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-04-01

Contact for this trial

Jon Lacy-Colson, FRCS

+44(0)1743261000 jon.lacy-colson@sath.nhs.uk

View on ClinicalTrials.gov More Colorectal Cancer trials